DUBLIN, Sept. 9, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) has voted to ...

Nebivolol tablets have a market value of roughly $978 million for the 12 months ending October 2021, according to IQVIA. Aurobindo has received The Food and Drug Administration’s blessing for ...

Patients with hypertension (high blood pressure) have a new generic medication to treat their condition. Camber is offering nebivolol tablets. The medication is the generic of Bystolic. Camber’s ...

NEW YORK (CBS.MW) -- Mylan Laboratories reported positive results of a study of its nebivolol drug in elderly heart failure patients. The study, which was conducted in Europe with Italian drug company ...

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced the launch of Nebivolol Tablets, 2.5 mg, 5 mg, 10 mg, and 20 mg. ANI’s Nebivolol ...

New York, NY -A new beta blocker, nebivolol (Bystolic, Forest/Mylan), has been approved by the US FDA for the treatment of hypertension. The drug is a selective beta 1 blocker and has the added ...

Glenmark Pharmaceuticals Inc., USA (Glenmark) has received final approval from the United States Food & Drug Administration (FDA) for nebivolol tablets, 2.5 mg, 5 mg, 10 mg and 20 mg, the generic ...

Nebivolol represents the first generic version of Bystolic, a hypertension drug developed by Allergan’s subsidiary Forest Laboratories. Bystolic posted annual sales of about $1 billion for the ...

Nebivolol is already registered and successfully marketed in more than 50 other countries outside of North America for the treatment of hypertension. Forest licensed nebivolol from Mylan in January ...

MANHATTAN (CN) — The manufacturer of a lucrative blood pressure drug did not violate antitrust laws by paying competitors to delay the market entry of the drug’s generic version, the Second Circuit ...